[
    {
        "utterance": "Yan Jiao Zhou: skilled sequencing, which I think is our access to be large uh you know, to genome skilled sequencing not only just that ",
        "annotations": {
            "propose new idea": "The speaker introduces a perspective on 'skilled sequencing' and its implications, which can be seen as introducing a new idea.",
            "develop idea": "The speaker elaborates on 'skilled sequencing', specifying its relation to accessing large genome sequencing."
        }
    },
    {
        "utterance": "Barbara Bendlin: I'm a neuroscientist by training but really more of an integrated biologist. I'm very interested in gut brain interactions in the context of cancer and specifically chemo. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own background and interests, signaling her expertise or qualifications related to the task or topic."
        }
    },
    {
        "utterance": "Mei Shen: and I use a lot of rodent models, but we also do some work in breast cancer patients. I'm Stephanie Clona. I'm at the University of Illinois at Chicago and I am trained as a mass spectrometrist. So my lab primarily does proteomic and lipidomic profiling and investigations to understand neurodegeneration and we actually work on a subset of disorders, lysosomal storage diseases that have neurodegenerative phenotypes. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their background and expertise as a mass spectrometrist.",
            "develop idea": "The speaker elaborates on their work, explaining what their lab primarily does and the specific areas they investigate."
        }
    },
    {
        "utterance": "Barbara Bendlin: So I'm pretty excited to learn more about um really the interplay and that space and perhaps how our tools and our expertise can play a role. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: My training is in chemical biology and my group works on developing chemical tools and different omics techniques. ",
        "annotations": {
            "signal expertise": "Chris Whidbey is explicitly stating their own expertise or qualifications related to the task."
        }
    },
    {
        "utterance": "Michael Burton: I can go next. So my name is Michael Burton. I am a fourth year assistant professor at the University of Texas at Dallas. ",
        "annotations": {
            "signal expertise": "The speaker is explicitly stating his own professional background and qualifications."
        }
    },
    {
        "utterance": "Barbara Bendlin: She can't. ",
        "annotations": {
            "process management": "This code applies because the utterance manages the interaction by stating someone's inability to participate or respond."
        }
    },
    {
        "utterance": "Shikha Nangia: My name is Shikha Nangia from Syracuse University. I'm trained in computational physiology and behavior, so how the immune system affects the brain. My lab is focused on studying protein protein interactions in cell membranes, receptors, the blood brain barrier architecture, the tight junctions and also bacterial membranes. So we study influx of metabolites in and out of the bacterial membranes to whole body behaviors and metabolism metabolic functions. So I'm interested in understanding how metabolites and cells get inside through tight junctions or through the cell membranes themselves and in our context of feeding. ",
        "annotations": {
            "signal expertise": "The speaker explicitly mentions their training in computational physiology and behavior, and describes their lab's focus and areas of study."
        }
    },
    {
        "utterance": "Michael Burton: Thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Hi, I think that I may be an outlier here. ",
        "annotations": {
            "identify gap": "Barbara Bendlin recognizes her potential difference or lack of fit within the group, indicating a gap in her expertise or perspective.",
            "signal expertise": "By mentioning her background and then quickly downplaying it, she is also subtly signaling her expertise while expressing her concern about being an outlier."
        }
    },
    {
        "utterance": "Erin Longbrake: Hi, I think that I may be an outlier here. So I study multiple sclerosis and the uh microbiome as an immunomodulator if you will for autoimmune disease. And so I'm doing some studies of the microbiome but also wanted to include metabolomics as well. So interested in understanding a bit more. ",
        "annotations": {
            "signal expertise": "Erin states her area of study and expertise in multiple sclerosis, microbiome, and her interest in including metabolomics.",
            "identify gap": "Erin mentions a gap in her current work by stating she wants to include metabolomics.",
            "clarify goal": "Erin clarifies her goal of understanding more about including metabolomics in her studies."
        }
    },
    {
        "utterance": "Barbara Bendlin: Thanks Erin. I'm clinical translational too so clinical and chemical biologist. Um but we also have Angela from our CSA for reason sensors to um image the neurotransmitters in the brain. ",
        "annotations": {
            "acknowledge contribution": "Barbara thanks Erin for her introduction.",
            "signal expertise": "Barbara explicitly states her own expertise as a clinical translational, clinical, and chemical biologist."
        }
    },
    {
        "utterance": "Barbara Bendlin: I think everybody is aware that we are in the metabolites and ions and small molecules. And we have some probing questions. So there's actually my call to the microbiome to choose a facilitator because we're going to download the slide deck and not facilitator, note taker I should say. ",
        "annotations": {
            "process management": "The speaker is managing meeting flow by informing the group about next steps and organizing activities.",
            "assign task": "The speaker is assigning the task of choosing a facilitator (or note taker) to the microbiome group."
        }
    },
    {
        "utterance": "Barbara Bendlin: Um and it's going to be the person who will report out to the larger group as well. Um do we have any volunteers? Does anybody want to take notes? ",
        "annotations": {
            "process management": "The speaker is managing meeting flow by asking for volunteers to take notes and report out to the larger group.",
            "assign task": "The speaker is assigning the task of taking notes to a group member.",
            "encourage participation": "The speaker is inviting others to participate by volunteering for a specific role."
        }
    },
    {
        "utterance": "Chris Whidbey: Yes, I can. ",
        "annotations": {
            "process management": "Chris Whidbey is agreeing to take notes, which is a task related to managing the meeting process."
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay great thanks Chris. Do you have access to the um Google Drive folder? ",
        "annotations": {
            "ask question": "The speaker is requesting information from Chris about his access to the Google Drive folder.",
            "process management": "The speaker is managing the team's process by ensuring that members have access to necessary resources like the Google Drive folder."
        }
    },
    {
        "utterance": "Chris Whidbey: Yes, I do. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a simple affirmative response to a question."
        }
    },
    {
        "utterance": "Barbara Bendlin: Fantastic. So my lab wrote some software that interprets the patient's behavioral state from the electrical signals recorded with the implanted devices. ",
        "annotations": {
            "signal expertise": "The speaker is sharing information about her lab's software, which indirectly signals her expertise in the field.",
            "develop idea": "The speaker is providing more information about her lab's work, which can be seen as developing the context of her expertise."
        }
    },
    {
        "utterance": "Richard Wiener: You can take notes as you go along and put them in there or you can take notes on another screen and then transfer the important points in at the end whatever is convenient for you to do. ",
        "annotations": {
            "process management": "This code applies because Richard Wiener is providing instructions on how to manage note-taking during the meeting, which is a part of managing the meeting's flow and organization."
        }
    },
    {
        "utterance": "Chris Whidbey: I'm probably going to take notes by hand because I'm analog like that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Richard Wiener: All right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay. There there's some panels at the bottom of my screen. Oh these these might be observers. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance based on the provided definitions."
        }
    },
    {
        "utterance": "Richard Wiener: Those those folks are just observing the conversations you guys can get going on. ",
        "annotations": {
            "process management": "Richard Wiener is managing the meeting flow by addressing the observers and suggesting the group can get going."
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay great. ",
        "annotations": {
            "Supportive Response": "The utterance expresses agreement or validation for a previous statement without adding new content."
        }
    },
    {
        "utterance": "Alda Ebrahimi: So my expertise we work on developing sensors and diagnostics to for example let's say if we know or we have some hypothesis and then we can work on building a sensor or a platform to monitor in real time. ",
        "annotations": {
            "signal expertise": "Alda Ebrahimi explicitly states her own expertise related to developing sensors and diagnostics.",
            "develop idea": "She briefly elaborates on her expertise in developing sensors and diagnostics based on hypotheses."
        }
    },
    {
        "utterance": "Richard Wiener: Oh yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Richard Wiener: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a minimal acknowledgment without additional content."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input, even if briefly."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "acknowledge contribution": "The speaker is verbally recognizing another group member's input, even if briefly."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a minimal acknowledgment without additional content."
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alda Ebrahimi: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: of the liver would be a very specific organ, you know, giving hormones, giving like the, on the same time they can look at the bile acids that are produced by the metabolic activity and they can measure the metabolic activity and the bacterial cells, they can measure their motion and their adhesion and their propagation in in in situ without needing to disrupt the nice cell of and also via inter interhepatic regulation. I don't know, circulation or enterohepatic circulation and that helps. So in an on this structure we can actually look at that, you know, lipids that could be produced by liver and then in turn fed to the microbiome. Who knows what happens to those um ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing topic by providing more details about the liver's functions and potential measurements.",
            "propose new idea": "The speaker introduces the liver as a specific organ of interest for study.",
            "ask question": "The speaker seeks information about the fate of lipids produced by the liver."
        }
    },
    {
        "utterance": "Barbara Bendlin: So maybe rather, you know, maybe I know everybody's written something down, but perhaps we could do it this way. Um, are there, do you want to, does anybody want to comment on on Aida's observation or on any of these mechanisms? ",
        "annotations": {
            "process management": "This code applies because Barbara Bendlin suggests a different approach to handling the discussion or sharing of information.",
            "encourage participation": "This code applies because Barbara Bendlin explicitly asks for comments or opinions from others regarding Aida's observation and the mechanisms discussed."
        }
    },
    {
        "utterance": "botB1: Would it be helpful if I just shared my screen so you could all see the notes I'm typing up while we go? ",
        "annotations": {
            "process management": "The speaker is suggesting a method to manage the meeting process more effectively by sharing their screen to show real-time notes."
        }
    },
    {
        "utterance": "Barbara Bendlin: Sure. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a simple acknowledgment or agreement without adding substantial content to the conversation."
        }
    },
    {
        "utterance": "botB1: Cool. ",
        "annotations": {
            "supportive response": "The speaker expresses a positive evaluation or agreement with the previous suggestion to share their screen.",
            "None": "No additional codes apply as the utterance is very brief and only expresses agreement."
        }
    },
    {
        "utterance": "botB1: Thank you, that would be great. ",
        "annotations": {
            "acknowledge contribution": "botB1 is verbally recognizing Barbara Bendlin's input.",
            "supportive response": "botB1 is expressing a positive sentiment towards the suggestion.",
            "process management": "botB1 is facilitating the meeting process by responding to Barbara Bendlin's suggestion."
        }
    },
    {
        "utterance": "Yanjiao Zhou: So I think um the developing barrier as well as the membrane to the immune system. those are obviously related to once the bacteria are secreted the ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing the relationship between the developing barrier, membrane to the immune system, and bacteria secretion."
        }
    },
    {
        "utterance": "Aida Ebrahimi: No, no, no, they are secreted. So like in the extracellular solution. And these are in the so whatever they, so let's say they are metabolizing something, they uptake that thing and from the environment. So we can monitor the level of that. ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous idea or discussion about biological processes, specifically about the secretion and monitoring of substances.",
            "clarify goal": "The speaker is providing more details about their work or a process, which can be seen as clarifying goals or methods."
        }
    },
    {
        "utterance": "Barbara Bendlin: Can I just chime in and maybe this is a little bit of a naive question, but um as someone who ",
        "annotations": {
            "ask question": "The speaker is about to ask a question, seeking clarification or input on a topic, as indicated by 'Can I just chime in and maybe this is a little bit of a naive question, but um as someone who'."
        }
    },
    {
        "utterance": "Aida Ebrahimi: depending what it is because it can make a sensor if it is really if if it is permeable. That's the question. You know, kind of connection. But if they are, if their amount is changed in the extracellular metabolite solution. And because of these interactions, we can monitor ",
        "annotations": {
            "ask question": "The speaker asks a question about the feasibility of making a sensor if it is permeable.",
            "develop idea": "The speaker elaborates on how interactions can be monitored based on changes in metabolite solution."
        }
    },
    {
        "utterance": "Barbara Bendlin: So if they continue like what ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on a prior statement or idea."
        }
    },
    {
        "utterance": "Aida Ebrahimi: what about other molecules? Is there if we know what they are. That's a big if. ",
        "annotations": {
            "ask question": "The speaker is explicitly requesting information about other molecules and their relevance, given certain conditions.",
            "identify gap": "The speaker is also highlighting a potential gap in knowledge or consideration of other molecules, conditional on them being known."
        }
    },
    {
        "utterance": "Yanjiao Zhou: maybe it is also related to the ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: if we need too much focus just on small molecules and not on biomarkers, you know, what are identifying what are those? So um I think maybe some of the, you know, maybe there is an overlap in terms of like the first question ",
        "annotations": {
            "ask question": "Aida is explicitly asking a question about focusing on small molecules versus biomarkers and inquiring about identifying them.",
            "clarify goal": "Aida is also seeking clarity on the goals or focus of their research by questioning the emphasis on small molecules over biomarkers."
        }
    },
    {
        "utterance": "botB1: What is a small molecule to me? Like a primary or secondary metabolite? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on what constitutes a small molecule, specifically if it refers to a primary or secondary metabolite."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I think in some sense they are also, you know, we are talking about biomarkers. And maybe that's a definition issue amongst the field that I don't understand. Um, so for example, you know, when Bob was today talking about short fatty acids. So that's a biomarker. So let's say we can build a sensor to monitor the level of those. And ",
        "annotations": {
            "develop idea": "She is expanding on the concept of biomarkers and how they could be monitored.",
            "identify gap": "She mentions a potential issue with definitions within the field."
        }
    },
    {
        "utterance": "Ashley Ross: Hi. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Shikha Nangia: Sure. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Ashley Ross: Go ahead, Ashley. Um, immune cells, you know, peripheral immune factors. Um, you know, as you know, you know, there's been the recent discovery of the lymphatic system and how, you know, the lymphatic system acts as a conduit for a lot of these peripheral immune factors. ",
        "annotations": {
            "propose new idea": "The speaker introduces concepts of immune cells and lymphatic system's role."
        }
    },
    {
        "utterance": "Aida Ebrahimi: That's a very interesting point. ",
        "annotations": {
            "supportive response": "Aida Ebrahimi is expressing a positive evaluation of Ashley's contribution, showing agreement and interest in the point made."
        }
    },
    {
        "utterance": "Ashley Ross: And it's not just the the BBB in of itself, you know, there's been the recent discovery of the lymphatic system and how, you know, the lymphatic system acts as a conduit for a lot of these peripheral immune factors. Um, you know, as you know, you know, usually we think about the brain and microglia as intrinsic, you know, macrophage of the brain, but we also know that peripheral macrophages, uh, and T cells are also able to cross the BBB. Um, we don't really have the sensitivity to image the BBB except to say like, you know, if I had a giant gleoblastoma, we can tell you that it's ostensibly pretty leaky at that point. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about the brain, immune system, and their interactions.",
            "identify gap": "The speaker mentions a limitation in sensitivity to image the BBB, which can be seen as identifying a gap in current knowledge or capabilities."
        }
    },
    {
        "utterance": "Shikha Nangia: So I'd like to talk about the computational approach to all the things that have been discussed. I think that's I think what you're really hitting on is sort of the challenge question, right? Is it the short chain fatty acids we talk about ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of discussing the computational approach to the topics that have been discussed.",
            "ask question": "The speaker asks for input or clarification on focusing on short chain fatty acids as a challenge question.",
            "develop idea": "The speaker is expanding on previous discussions by suggesting a computational approach."
        }
    },
    {
        "utterance": "Yanjiao Zhou: So does that continue like what conversation? In fact, there's a lot of traffic in the healthy state. is another transmitter that have a ",
        "annotations": {
            "ask question": "The speaker is seeking clarification or continuation of a previous conversation, explicitly asking a question.",
            "None": "No additional codes seem to apply as the utterance is primarily about asking a question for clarification."
        }
    },
    {
        "utterance": "Ashley Ross: Go ahead, Ashley. ",
        "annotations": {
            "encourage participation": "The speaker is inviting another group member to contribute their thoughts or ideas, thereby encouraging participation.",
            "supportive response": "The utterance is also a supportive response as it provides a positive and encouraging environment for the invited speaker to share their thoughts."
        }
    },
    {
        "utterance": "Ashley Ross: So my lab actually we've done electrochemical measuring norin, dopamine, serotonin, melatonin. And it's not just the the BBB in of itself, you know, there's been the recent discovery of the lymphatic system and how, you know, the lymphatic system acts as a conduit for a lot of these peripheral immune factors. Um, you know, as you know, you know, peripheral macrophages, uh, and T cells are also able to cross the BBB. Um, we don't really have the sensitivity to image the BBB except to say like, you know, if I had a giant gleoblastoma, we can tell you that it's ostensibly pretty leaky at that point. ",
        "annotations": {
            "identify gap": "The speaker mentions a limitation in their ability to image the BBB."
        }
    },
    {
        "utterance": "Shikha Nangia: But you know, to go back to Stephanie's point, you know, I think that's I think what you're really hitting on is sort of the challenge question, right? Is it the short chain fatty acids that are generated by the gut microbiota that just that drive a lot of these physiologic changes that we see. Or is it the intrinsic physiologic things that are mediated certain metabolites. Um, so I'm trying not to leave out trimethylamine oxide. And actually trimethylamine oxide is generated by uh FMO oxidation. So that's kind of getting to the sort of system. So if you know the walls of the two, you know, the epithelial cells and bacteria, but if you know the metabolites, the communication ",
        "annotations": {
            "develop idea": "The speaker is building upon an existing idea by referring back to Stephanie's point and elaborating on it.",
            "ask question": "The speaker poses a question about the role of short chain fatty acids versus intrinsic physiologic things mediated by certain metabolites."
        }
    },
    {
        "utterance": "Shikha Nangia: And so, you know, there are these other sort of inflammatory cascades that Jay actually might know more about. And so, you know, there are these other sort of inflammatory cascades that Jay actually might know more about. And so, you know, there are these other sort of inflammatory cascades that Jay actually might know more about. And so, you know, there are these other sort of inflammatory cascades that Jay actually might know more about. ",
        "annotations": {
            "signal expertise": "The speaker suggests that Jay actually might know more about inflammatory cascades."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Yeah, so you might have, we do have a lot of this paired data set. We have humoral, so any signaling pathways through the blood could be affected by cardiovascular health if not cardiovascular. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by mentioning available paired data sets and their potential relevance to signaling pathways through the blood and cardiovascular health."
        }
    },
    {
        "utterance": "Shikha Nangia: Absolutely. I mean it's kind of like what we're talking about with the blood brain barrier, um how intact it is. ",
        "annotations": {
            "Supportive response": "The speaker expresses agreement and validates previous discussions.",
            "Develop idea": "The speaker relates their point to a previously discussed topic (the blood-brain barrier), expanding on existing ideas."
        }
    },
    {
        "utterance": "Erin Longbrake: It does become important for access to the brain might impact how cognitive information, if you have a good clinical of your just the amount of heterogeneity that there is in the brain and this is one of the places where a lot of the existing microbiome and metabolome research falls short. I agree with you about the potential but I would say that part of the what we were thinking feeding into those models would be end up. Yeah, I think I mean as a mass spectrometrist, I think the biggest challenge and I don't do metabolomics, but the biggest challenge with it is is that um many metabolites have not been defined. ",
        "annotations": {
            "develop idea": "The speaker elaborates on the challenges of metabolomics and its relevance to understanding brain heterogeneity."
        }
    },
    {
        "utterance": "Shikha Nangia: I agree with you that a successful pattern definition is a big data. And so untargeted is is really powerful because you can find a lot of signals that are changing but deducing that untargeted signal to a structure and understanding its function is really a bottleneck. We have to have detailed information to say this is what we need to cure this disease. I I I would echo that sort of. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement with a previous statement.",
            "develop idea": "The speaker expands on an existing idea by discussing the challenges and benefits of using untargeted approaches in metabolomics."
        }
    },
    {
        "utterance": "Shikha Nangia: And so yes, maybe the bottleneck is getting that big data right now because the tools so far to visualize are getting developed in other fields, not microbiota, but they will become available once we have the data. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the challenges faced in their research area, specifically discussing the bottleneck of big data and visualization tools.",
            "identify gap": "The speaker explicitly mentions a bottleneck, implying a gap in current capabilities regarding big data and visualization tools."
        }
    },
    {
        "utterance": "Flavio Frohlich: Um, so we we have done work with is um target panel. So that gets by and uh uh focusing on metabolites that are produced or co-produced. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas or methods by sharing their own experience with a target panel and how it applies to focusing on certain metabolites.",
            "signal expertise": "By stating they have done work with a target panel, Flavio Frohlich is explicitly stating his group's expertise or experience in the area of metabolomics."
        }
    },
    {
        "utterance": "Shikha Nangia: I think in this question I identify. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: You know, it's you mentioned in other fields. For example, so we work a lot on material engineering and there are a lot of nanomaterials. So I know I personally don't work on energy for catalysis, but I know there are a lot of computational works that are starting from the first principle calculations and then coupling them with AI to really screen a bunch of different transition metal chalcogenides and chalcogenates to see how they interact with hydrogen and oxygen, very simple molecules to um for energy, for hydrogen evolution reaction or you know, basically for catalysis, you know, catalyzing those reactions. And then AI coupled with first principle calculations identify what are the type of defects or what transition metals that can actually be thermodynamic stable to make them and they are good to um for that application. And so then they guide the experimentalist that you know, don't build your material, molydenum disulfide for example with manganese. It is good, it is it is good for HER process for this catalytic process. And there has been a lot of discoveries actually that are like um again, I I I think in terms of the super conductivity that's also the same. They were actually started with computational results and they predicted that this is going to be like with a 1.1 degree for example you are going to get super conductivity. It started with and then people could do it. So you just focus on it. ",
        "annotations": {
            "signal expertise": "Aida Ebrahimi explicitly states her background and work in material engineering and computational methods.",
            "develop idea": "She is elaborating on how computational methods can be applied in a specific field, potentially to inspire or inform the group's discussion."
        }
    },
    {
        "utterance": "Flavio Frohlich: And um these restricted diets and the thing that I keep coming back to of very low levels of uh endogenous short chain fatty acid production like Dr. Brian was just talking about. ",
        "annotations": {
            "develop idea": "The speaker is referring to and building upon a previous idea about short chain fatty acid production, indicating a development of the discussion."
        }
    },
    {
        "utterance": "Barbara Bendlin: I was I was wondering if I could ask Claudia. ",
        "annotations": {
            "ask question": "The speaker is requesting to ask Claudia a question, indicating a need for information or clarification."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: I know you're busy taking notes but you can also comment and you know what when we get to 2 o'clock will work together to help you summarize and report out like it's not all going to be on you. I think we report out. ",
        "annotations": {
            "encourage participation": "Barbara Bendlin is encouraging Chris Whidbey to participate in the discussion by saying 'you can also comment'.",
            "process management": "Barbara Bendlin is managing the meeting process by mentioning that they will work together to summarize and report out."
        }
    },
    {
        "utterance": "Chris Whidbey: Over connected. ",
        "annotations": {
            "process management": "The speaker is commenting on a technical issue related to the meeting setup, indicating a problem with being 'over connected'."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I guess. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: And um these restricted diets the thing that I keep coming back to of very low levels of uh endogenous short chain fatty acid production like Dr. Brian was just talking about comes up in these types of conversations. And as it turns out is what allows to undergo snap meaning. ",
        "annotations": {
            "develop idea": "The speaker expands on a previous idea by referencing Dr. Brian's statement about endogenous short chain fatty acid production.",
            "acknowledge contribution": "The speaker acknowledges a previous contribution by Dr. Brian.",
            "supportive response": "The tone of the utterance is supportive, building upon previous discussions."
        }
    },
    {
        "utterance": "Barbara Bendlin: I was I was wondering if I could ask. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Amina Schartup: No. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Sarah, we've done some studies looking at the linings of the gut which are stimulated by which can be stimulated by the gut microbio to um computational models and how are you looking at the metabolites from the guts like and. ",
        "annotations": {
            "ask question": "The speaker is asking about how another group is looking at metabolites from the gut.",
            "develop idea": "The speaker is expanding on previous discussions by mentioning their studies and asking about another group's approach."
        }
    },
    {
        "utterance": "Flavio Frohlich: That's a great question. This is a little bit outside of what we're doing so much but we're kind of starting to think about it. ",
        "annotations": {
            "identify gap": "The speaker recognizes that the topic is outside their current focus, indicating an awareness of a gap in their work.",
            "supportive response": "The speaker starts by saying 'That's a great question,' which is a positive evaluation of the question asked."
        }
    },
    {
        "utterance": "Amina Schartup: I'm not doing any of that. I don't work with microbes. I wonder if that relates to the novelty, like the novel object responses that you see. So I'm interested. Like I said, I'm a trace metal chemist. I study mostly mercury cycling in the environment. And so the the reason I'm here is because I've been interested for a while in thinking about um gut microbiome. ",
        "annotations": {
            "identify gap": "Amina recognizes her lack of work with microbes and her interest in gut microbiome, showing an awareness of a gap in her expertise.",
            "signal expertise": "Amina clearly states her expertise as a trace metal chemist and her work on mercury cycling.",
            "ask question": "Amina asks a question about the relation to novelty and 'novel object responses'."
        }
    },
    {
        "utterance": "Amina Schartup: I wonder if that relates to the novelty. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification about a potential relationship between two concepts."
        }
    },
    {
        "utterance": "Amina Schartup: Um, not not not the novelty, so I'm I'm interested like I said, I'm a trace metal chemist. I study mostly mercury cycling in the environment. And so the the reason I'm here is because I've been interested for a while in thinking about um gut microbiome. What about the other direction? What about the brain to the gut? And so the question that I got from this morning is are those um you know, assets that are being produced are they there to support or are they certain molecules that are there to support a more varied and diverse system? And so the variety of the system is what I'm thinking about. That's really what I am interested in. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise as a trace metal chemist studying mercury cycling in the environment.",
            "ask question": "The speaker asks questions about the interaction between the brain and the gut microbiome, and the role of molecules in supporting system diversity.",
            "identify gap": "The speaker indicates an interest in understanding the brain to gut interaction, suggesting a gap in her current knowledge."
        }
    },
    {
        "utterance": "Chris Whidbey: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mei Shen: I mean I'm pretty new to the field, right? I'm really learning. ",
        "annotations": {
            "identify gap": "Mei Shen explicitly states her lack of familiarity with the field and her current position as someone who is learning."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: Of the gut. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Yanjiao Zhou: Of the gut. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: Yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Yanjiao Zhou: Yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mei Shen: So this is my last question was asking, right? How do they like specifically influence? I mean, I'm also curious about that like how many different kinds of bacteria in the gut. ",
        "annotations": {
            "ask question": "The speaker is requesting information about how certain factors specifically influence and about the number of different kinds of bacteria in the gut."
        }
    },
    {
        "utterance": "Chris Whidbey: Patients who often experience uh profound GI symptoms and and thought to have this. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey-Seattle University (he/him): this neurotype that restricts your diet doesn't allow you to test those already. I'm particularly interested in is it's like this autotoxic other metabolites, what other small molecules. So that's like one other way that the brain can the gut because they end up in that like, you know, that like half of it is unknown one unknown to unknown. ",
        "annotations": {
            "ask question": "The speaker is inquiring about the relationship between certain factors and metabolites.",
            "develop idea": "The speaker is elaborating on his interest in certain metabolites and their interaction with the brain and gut.",
            "identify gap": "The speaker notes the unknown aspects of brain-gut interactions."
        }
    },
    {
        "utterance": "Aida Ebrahimi (Penn State University): So another thing I think that would be interesting is how neuro not like gut brain axis place a super important role. So how I guess how these connections with agents when we're running but if it's unknown different kind of effects on those um. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea to explore the gut-brain axis and its importance.",
            "ask question": "The speaker asks about the effects of connections with agents, particularly when they are unknown or different."
        }
    },
    {
        "utterance": "Chris Whidbey-Seattle University (he/him): the same is true for hypothetical genes in a metagenomics data set. The techniques are are getting better to get annotation and to describe particular genes. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing topic by providing more information about the techniques for annotating and describing particular genes in metagenomics data sets."
        }
    },
    {
        "utterance": "Aida Ebrahimi (Penn State University): So there are all these students, but then what are the approaches actually to study these um, system level, so what's a common approach that people use for such kind of discoveries? ",
        "annotations": {
            "ask question": "The speaker is requesting information about approaches used for studying complex systems and making discoveries, which aligns with the definition of asking a question to gather information."
        }
    },
    {
        "utterance": "Chris Whidbey-Seattle University (he/him): Some kind of maybe big data approach to identify those unknowns that are really important that you can then maybe use some computational spectra analysis. ",
        "annotations": {
            "propose new idea": "The speaker suggests using a big data approach and computational spectra analysis to identify unknowns, which is a new methodological suggestion."
        }
    },
    {
        "utterance": "Erin Longbrake - Yale: That's all. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin (she/her) University of Wisconsin-Madison: That does relate to the gut immune axis question as well, which is how, you know, how do we how do we identify those that are related to the gut that are being secreted by the microbiota. You need to perturb the system to then find those. ",
        "annotations": {
            "ask question": "The speaker is asking for a methodological approach to identify substances secreted by the microbiota.",
            "offer feedback": "The speaker provides a suggestion on how to proceed with identifying these substances."
        }
    },
    {
        "utterance": "Erin Longbrake - Yale: And and and I'll add to that that the gut is not as just uniform, you know, there's a lot of concern that we're looking at fecal microbiome that doesn't represent the local effects on the bacterial community itself and how that interacts with the host and you have effects on let's just say epithelial and endothelial cells. In terms of so to back to your question about what kind of approaches people sort of take to the system. you know, obviously there are many ways so so some of the approaches on nerve endings. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous discussions about the gut microbiome, its complexities, and the challenges in studying it, providing more insight into the concerns and considerations in the field.",
            "None": "No other codes seem to apply as directly or explicitly as 'develop idea'."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): Well, that gives me an idea for you have this discussion going on. So suppose I'm just going to hypothetically come up with an experiment. Uh, suppose we have mice which have no uh microbiota in it, like Baba showing initially. And then we say, okay, can we uh specific microbiota of say one or two species that we know, you know, bacterial species that we know. And I think that gives you an idea of where you have the discussion going on. So suppose I'm just going to hypothetically come up with an experiment. Uh, suppose we have mice which have no uh microbiota in it, like Baba showing initially. And then we say, okay, can we uh specific microbiota of say one or two species that we know, you know, bacterial species that we know. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea for a hypothetical experiment involving mice with no microbiota and introducing specific microbiota to study its effects."
        }
    },
    {
        "utterance": "Flavio Frohlich (he/him) - UNC: That's a great question. ",
        "annotations": {
            "supportive response": "Flavio is expressing a positive evaluation of the question asked, showing agreement and appreciation for the discussion."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): I agree with you. I guess that particular species of bacteria might help colonize. And then you can progressively increase the complexity of the microbiota that is introduced. And see how the metabolite uh big data approach. I know from other colleagues that I work with that there's synergy in some species with each other and there's one species that's more dominant. So if you start drawing those diagrams, when you have these two species overlapping each other, then you have the high dimensional system, things things actually work a little bit differently. So for example, you know, we train our neural nets for object recognition. ",
        "annotations": {
            "supportive response": "The speaker agrees with a previous statement."
        }
    },
    {
        "utterance": "Erin Longbrake - Yale: In one case. ",
        "annotations": {
            "develop idea": "Erin is introducing a specific case to elaborate on a previous point or idea discussed in the conversation."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): So hypothetically, you know, wild idea, but I think we need to grow that database of which particular species is responsible for a particular metabolite and then the interdependence because I'm sure one one kind of bacteria species is not going to be able to do that. So if you start drawing those diagrams, when you have these two species overlapping each other, then you have the high dimensional system, things things actually work a little bit differently. So for example, you know, we train our neural nets for object recognition. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea about growing a database to understand the relationship between bacteria species and metabolite production.",
            "develop idea": "The speaker elaborates on the idea by suggesting a hypothetical experiment to test the interactions between different bacteria species and metabolite production."
        }
    },
    {
        "utterance": "Flavio Frohlich (he/him) - UNC: I'm just listening to all this and this is really amazing. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and positive evaluation for the conversation, showing engagement without adding new content."
        }
    },
    {
        "utterance": "Mei Shen, University of Illinois at Urbana-Champaign: So so this is yeah, I I think is the idea millions of features but there are many steps you can take to really reduce the number of you know, feature selection but many of the features are highly correlated. So the network approach that there are many different ways to network approach. So I guess then you could link to the ",
        "annotations": {
            "develop idea": "Mei Shen is expanding on existing ideas by discussing methods to reduce the number of features in data analysis, such as feature selection and network approaches."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): I agree with you. I guess that particular species of bacteria might help colonize. And then you can progressively increase the complexity of the microbiota that is introduced. And see how the metabolite uh big data approach. I know from other colleagues that I work with that there's synergy in some species with each other and there's one species that's more dominant. So if you start drawing those diagrams, when you have these two species overlapping each other, then you have the high dimensional system, things things actually work a little bit differently. So for example, you know, we train our neural nets for object recognition. ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas by discussing the introduction of specific microbiota and the complexity of their interactions.",
            "offer feedback": "The speaker provides a hypothetical approach to studying the effects of specific bacteria species on microbiota.",
            "acknowledge contribution": "The speaker agrees with a previous statement, acknowledging another participant's input."
        }
    },
    {
        "utterance": "Flavio Frohlich (he/him) - UNC: So the problem with that then is you can't actually flip the problem on its head then and have model building too. ",
        "annotations": {
            "critical response": "The speaker is pointing out a problem with the approach to model building, indicating a critical response to a previous idea."
        }
    },
    {
        "utterance": "Shikha Nangia (Syracuse University): I know it's good but this is what I'm hearing is there's a lot of experts will have to help in trying to sort of uh say, you know, what is the best way to proceed with that experiment but with the uh the limitation of just having so much. ",
        "annotations": {
            "signal expertise": "The speaker mentions the need for a lot of experts to help in trying to proceed with the experiment.",
            "identify gap": "The speaker discusses the limitation of just having so much, implying a gap in resources or data.",
            "supportive response": "The speaker is providing a constructive comment by acknowledging the complexity and suggesting a way forward."
        }
    },
    {
        "utterance": "Flavio Frohlich: Uh and then next is uh individuals, we do next is kind of rank ordering uh to kind of map out the space of configurations. Because all those pathways, you say have 50 pathways, they're not all going to contribute to and understand how. Okay, how do we use statistical methods and biological prior knowledge to find the top three that could actually be linked to phenotype. And then that's when you start talking with biologists and then begging them to um to do like experimental validation. Um also something uh JP, you would know this like since you're in radiology, um you know, looking at brain images. I mean brain images of like maybe possibly areas of depending on what areas light up in a particular patient. I'm very new about how brain imaging works, but you know, people start have started you know, some of the recent Alzheimer's papers that I've just I've just reading just out of pure interest. I mean they do FM fMRI imaging and see what areas light up and does that have any statistical correlates with um you know, gut microbiome features or other features in the blood. ",
        "annotations": {
            "develop idea": "The speaker is expanding on how to approach the analysis of pathways and their links to phenotypes.",
            "identify gap": "The speaker identifies a gap in their knowledge, specifically about brain imaging.",
            "encourage participation": "The speaker engages with others, mentioning JP and their potential knowledge."
        }
    },
    {
        "utterance": "Erin Longbrake: It's actually a couple years ago to that exact question. Um so what we did was we took mice, we transplanted um different gut microbial populations into them. So we had like like in four or five different groups and then we quantitatively imaged the brain. ",
        "annotations": {
            "develop idea": "The speaker is describing a specific research study they conducted, providing details on methodology and approach.",
            "offer feedback": "By sharing their research approach, the speaker is indirectly suggesting a method for others to consider in their own studies."
        }
    },
    {
        "utterance": "Shikha Nangia: So talking about what we just heard, what are the changes from young to old microbiome? That is the longitudinal study, which is what you just basically it's like large data set home and you just basically mash them together. So we did uh we did a K fold uh validation uh random forest supervised learning study. And we're able to show that you know, certain areas of the brain, there was structural change may actually say that's because we had this rosemary and we had this microstructural change over here and that's due to, you know, bifidobacterium in the gut. Which can make those statistical associations between gut microbial populations in the brain. The the problem with that as you know is these are pure statistical associations and actual biology is a little bit opaque. Like why do we see that? So it's hard to validate uh this sort of studies. ",
        "annotations": {
            "ask question": "The speaker asks a question at the beginning of the utterance, seeking information or discussion.",
            "develop idea": "The speaker expands on their research idea by discussing methodology and findings.",
            "identify gap": "The speaker identifies a limitation in their approach, recognizing that the actual biology underlying their statistical associations is not clearly understood."
        }
    },
    {
        "utterance": "Yanjiao Zhou: you know, people have done like longitudinal study and to say how. I mean, JP want to ask you a question. Uh you were talking about ranking these pathways in order that would be quite stable in the adults over time. What do you use to rank the pathways? Uh I think it's a challenge because there's so many ways to um you know, for example, there's many statistical ways to do this. I'll take the example of uh you know, gut microbiome data that people are looking into. So there are ways to do some type of permutation analysis, an over analysis. There's various statistical ways to kind of see what variance in particular microbial contributes most to uh the the clinical end point you have in mind. So let's say you have uh I'll just go back to my point earlier. Let's say you have like a thousand microbes. Yeah, you could kind of bin them down to particular principle components. Um which I'm sure many in the audience are familiar with that. And then see which principle components um correlates the most with uh with the clinical phenotype that you have. There's various statistical ways to do that. ",
        "annotations": {
            "ask question": "The speaker is asking for methods or statistical approaches used to rank pathways, specifically in the context of analyzing gut microbiome data and relating microbial variance to clinical endpoints."
        }
    },
    {
        "utterance": "Erin Longbrake: It also that it will be very useful to have a dictionary in that area. Where are the dominant bacteria and metabolites that are produced by those bacteria. ",
        "annotations": {
            "identify gap": "The speaker recognizes a lack of a useful resource (dictionary) for understanding dominant bacteria and metabolites.",
            "develop idea": "The speaker suggests a specific solution (creating a dictionary) to address the identified gap."
        }
    },
    {
        "utterance": "Chris Whidbey: I I part of the reason I asked the question is we've done some work with uh that's good information. But uh some of you already know. ",
        "annotations": {
            "supportive response": "Chris Whidbey is providing a supportive statement, acknowledging the information and their own previous work."
        }
    },
    {
        "utterance": "Erin Longbrake: So, uh I don't know, you know, sort of a dictionary like that. There are people that have been contributing more. ",
        "annotations": {
            "propose new idea": "Suggesting the idea of a dictionary-like resource for cataloging metabolites and bacteria.",
            "acknowledge contribution": "Recognizing that others have been contributing more to this area.",
            "supportive response": "Engaging positively with the conversation and idea of contributions."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Yeah, there are definitely established for those who haven't contributed as much. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges the contributions of others, implying that there are established references for those who have contributed significantly.",
            "supportive response": "The speaker expresses agreement or validation, implying support for the discussion."
        }
    },
    {
        "utterance": "Ashley Ross: I'm wondering. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Yanjiao Zhou: Oh, I'm thinking about like a global. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: Anyone else? ",
        "annotations": {
            "ask question": "The speaker is requesting information or opinions from others.",
            "encourage participation": "The speaker is inviting others to contribute their thoughts or opinions."
        }
    },
    {
        "utterance": "Ashley Ross: I I'm wondering, you know, there's been a lot of work done I was just just doing a pub med search on on organ on a chip, right? I'm wondering like do we should we reduce it, right? If we really want to understand the the role of reproductive microbiome, like should we make like a you know, reproductive system on a chip, you know, an ovary, a fallopian tube and the and understand the bacterial organ communication. I don't know, maybe I'm those I know we have my colleague who's on here, he's in lab. I don't know much about details, so yeah. ",
        "annotations": {
            "propose new idea": "The speaker suggests a novel approach of making a 'reproductive system on a chip' to understand the role of reproductive microbiome.",
            "ask question": "The speaker asks for input or consideration on whether to approach the study of reproductive microbiome by making a 'reproductive system on a chip'.",
            "encourage participation": "The speaker invites potential discussion or input from others, mentioning a colleague."
        }
    },
    {
        "utterance": "Mei Shen: I don't think you are. I I do agree that we have to do is is to focus on. ",
        "annotations": {
            "critical response": "The speaker expresses disagreement with a previous statement.",
            "supportive response": "The speaker also expresses agreement on focusing on something."
        }
    },
    {
        "utterance": "Flavio Frohlich: That's that's an interesting question at least in psychiatry is that we have to do is to take the images and predict when the neuron is going to spike. So you take the the data of the image and the spikes uh train your own net to to predict when the neuron is going to spike. And then once you do that, we can invert that process. So we can synthesize a bunch of images that are predicted to drive high firing rates in the neuron. ",
        "annotations": {
            "Develop idea": "The speaker explains their approach to analyzing images and predicting neuron spikes, which is an example of expanding on an existing idea through reasoning and methodology.",
            "Signal expertise": "The speaker mentions their experience and approaches used in psychiatry, indicating their expertise in the field."
        }
    },
    {
        "utterance": "Flavio Frohlich: So I wonder if if a sort of data driven scheme like that of taking microbiome observations predicting the disease pathologies and then inverting those predictors might also help in this case. Uh similar to where we can be relatively sure I assume that for a given disease label or diagnosis there are organ systems common biological alteration or pathology. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new suggestion for approaching the study of microbiome and disease relationships.",
            "develop idea": "The speaker expands on the proposed idea by detailing potential methodologies.",
            "ask question": "The speaker explicitly requests consideration or information about the potential utility of the proposed approach."
        }
    },
    {
        "utterance": "Amina Schartup: I guess I kind of have a question following up on that. ",
        "annotations": {
            "ask question": "Request information, clarification, or expertise from other team members on a prior statement or idea proposed by another group member."
        }
    },
    {
        "utterance": "Chris Whidbey: I neurobiology is not my not my background at all. Are there how how good are the models? Are there ways to do like high. ",
        "annotations": {
            "identify gap": "Chris Whidbey recognizes a gap in his expertise, stating neurobiology is not his background.",
            "ask question": "Chris Whidbey asks about the quality of models and methods in neurobiology."
        }
    },
    {
        "utterance": "Flavio Frohlich: Did I get anything? ",
        "annotations": {
            "ask question": "The speaker is requesting information or confirmation about whether he got something."
        }
    },
    {
        "utterance": "Chris Whidbey: Yeah, I mean, I I think um uh to to to to to the point about um like using um I I think well let me just speak to a couple of things I've heard. Uh try to reduce uh the complexity to I don't know how that to um so that the the the classic reductionist approach to isolate that which we're trying to to test the hypothesis. Um but then when we study the gut microbiome and the human. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing the complexity of studying the gut microbiome and mentioning a classic reductionist approach."
        }
    },
    {
        "utterance": "Flavio Frohlich: There are several people that are doing that. That's that's an interesting point. That's more an approach to common biological alteration or pathology. An important approach. ",
        "annotations": {
            "supportive response": "Flavio expresses agreement and validation for an approach to common biological alteration or pathology.",
            "acknowledge contribution": "Flavio acknowledges the work of others in a particular approach."
        }
    },
    {
        "utterance": "Barbara Bendlin: Yeah, I mean for I can just comment on Alzheimer's disease and having known pathological features. So now we have people biomarkers that we can use and then leveraging useful reference databases to figure out what those metabolites are. Um but as Aaron mentioned humans are very heterogeneous and medications and what people are eating and there's a lot of overlap. So you also have to really well define the disease phenotype. ",
        "annotations": {
            "develop idea": "The speaker elaborates on the challenges and considerations in studying Alzheimer's disease.",
            "signal expertise": "The speaker mentions her ability to comment on Alzheimer's disease.",
            "supportive response": "The utterance expresses a positive view towards using biomarkers and reference databases.",
            "identify gap": "The utterance highlights the challenges in studying human diseases, such as heterogeneity and overlap.",
            "clarify goal": "The speaker emphasizes the importance of defining disease phenotypes."
        }
    },
    {
        "utterance": "Barbara Bendlin: So so so I think I think from my perspective it's always been a challenge in um try to ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: neuro hypothesis likewise I'm friend of this complexity in humans that we don't have a lot of well defined biomarkers to follow with the clinical diagnosis. You know, so some some some approaches sort of try to interrogate many different systems that may be talking to each other and give us some signals to to to show that um this is indeed a biological condition. I think neurological conditions overall are heterogeneous and are complicated that have clearly defined and black and white. Not sure I'm going to answer just sort of throw out my my take on the the complexity especially at a system level. ",
        "annotations": {
            "identify gap": "Explicitly recognizing the lack of well-defined biomarkers for neurological conditions.",
            "develop idea": "Elaborating on the complexities and challenges in understanding neurological conditions.",
            "encourage participation": "Sharing her thoughts and uncertainties to foster discussion."
        }
    },
    {
        "utterance": "Flavio Frohlich: Yeah, and then on the most frustrating kind of aspect for me is how stable are these microbiome like within a person like if you look at it longitudinally, do they change very rapidly? Yeah, there's a lot of study being done on this on this um throughout lifespan and typically as we understand it, um microbiome is quite dynamic up till age three or four um and then has a fairly stable um uh ",
        "annotations": {
            "ask question": "The speaker asks a question about the stability of microbiomes within a person over time, indicating a request for information.",
            "None": "No other codes are explicitly observed in the utterance."
        }
    },
    {
        "utterance": "Barbara Bendlin: So for the ideal world, you know, if you had a traumatic perturbation whether it's antibiotics or um you know, traveler's diarrhea for example, those are kind of uh uh but short of these ",
        "annotations": {
            "clarify goal": "The speaker is discussing a hypothetical scenario related to understanding the impact of significant disruptions on the microbiome, which relates to defining or clarifying objectives."
        }
    },
    {
        "utterance": "Flavio Frohlich: Yeah, thanks thanks for asking this. So the adult I would probably go back to school observation, right? And start there for example, antibiotics have a um I guess that would kind of depend on what level of taxonomic range we're looking at at the file level or ",
        "annotations": {
            "express humor": "The speaker makes a joke or uses humor with the phrase 'go back to school observation'.",
            "offer feedback": "The speaker provides some feedback or suggestions for how to approach a problem."
        }
    },
    {
        "utterance": "Flavio Frohlich: So you know we know I think I would go for something like that, right? Where we have a perturbation that we know has a clear effect on the microbiome because I think of course the the universal there's no universal definition of strain but at the strain level it's actually pretty I would say dynamic and chaotic. ",
        "annotations": {
            "develop idea": "The speaker is discussing and elaborating on an approach to study the microbiome.",
            "identify gap": "The speaker highlights the lack of a universal definition of strain.",
            "offer feedback": "The speaker suggests using perturbations with known effects on the microbiome for study."
        }
    },
    {
        "utterance": "Flavio Frohlich: Yeah, and we know that that that that's indeed an area of psychiatric behavioral phenotypes that are transient and related to it. I don't know whether really that mechanism is um but that's probably where I start. And that wouldn't care about, you know, these people don't have any diagnosis so you avoid all that complexity of depression really is but you can assess ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing the complexity of psychiatric conditions and potential approaches to studying them.",
            "identify gap": "The speaker acknowledges not knowing if a certain mechanism is relevant, indicating a gap in knowledge."
        }
    },
    {
        "utterance": "Flavio Frohlich: Jeff Gordon at Washu has published a lot of research about the temporal dynamics and the sort of the overall stability of the microbiome and Jay is absolutely right it really depends on what level of taxonomic analysis we're doing this at. So um ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by mentioning Jeff Gordon's research and agreeing with Jay.",
            "signal expertise": "The speaker is showing their knowledge by referencing specific research and a researcher in the field.",
            "supportive response": "The speaker is supporting the discussion by agreeing with Jay and adding information."
        }
    },
    {
        "utterance": "Barbara Bendlin: So that works fine. if you're okay transcribing our our the question of like what does not affect the ",
        "annotations": {
            "process management": "The speaker is discussing the logistics of transcribing the conversation and managing the discussion."
        }
    },
    {
        "utterance": "Chris Whidbey: I'm opening it all. Um ",
        "annotations": {
            "process management": "The speaker is taking an action to manage the meeting flow by sharing information or a screen."
        }
    },
    {
        "utterance": "Barbara Bendlin: So then to Wingen's question is like I think there's two major questions from that. One is how much significance do we assign for more more specific phylogenetic ",
        "annotations": {
            "develop idea": "The speaker is expanding on a previous topic or question.",
            "ask question": "The utterance contains a question seeking clarification or opinion."
        }
    },
    {
        "utterance": "Erin Longbrake: I like Flavio's idea though. ",
        "annotations": {
            "supportive response": "Expressing agreement, validation, or positive evaluation for Flavio's idea without adding new content."
        }
    },
    {
        "utterance": "Chris Whidbey: So if I'm ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: looking through I feel like I can clump things into different categories and please let me know if I missing anything. I think that's another system then we can add the circadian circuitry. As far as kind of detection methods ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of considering the circadian circuitry as another system.",
            "develop idea": "The speaker expands on their thoughts about categorizing and adding new systems.",
            "ask question": "The speaker requests feedback on their approach and inquires about detection methods."
        }
    },
    {
        "utterance": "Chris Whidbey: So it seems like exist or can be developed but you'd have to know what you're trying to do that first step. Um so that seems like that's kind of one bottleneck is dealing with all of the unknown ",
        "annotations": {
            "identify gap": "Chris Whidbey identifies dealing with unknowns as a bottleneck in research.",
            "offer feedback": "Chris Whidbey provides feedback on the challenge of developing methods without clear objectives."
        }
    },
    {
        "utterance": "Chris Whidbey: I was going to say I I summarized the best that I could but I uh ",
        "annotations": {
            "summarize conversation": "Chris Whidbey mentions summarizing the conversation.",
            "supportive response": "Chris Whidbey is expressing a positive sentiment about his effort to summarize."
        }
    },
    {
        "utterance": "Barbara Bendlin: That's that's a great job. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and positive evaluation of someone's work."
        }
    },
    {
        "utterance": "Chris Whidbey: I was going to say I I summarized the best that I could but I uh ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: I'm going to share screen on it. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by offering to share his screen to facilitate discussion or presentation."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I'm going to say. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Okay. ",
        "annotations": {
            "acknowledge contribution": "Barbara Bendlin is acknowledging a previous statement or action, showing she is engaged and following the conversation."
        }
    },
    {
        "utterance": "Barbara Bendlin: So the there is just a note from uh Andrew that we should try to kind of summarize our key things and I think our aim is to eventually have like one slide with some of the key questions that we discussed. ",
        "annotations": {
            "process management": "The speaker is suggesting to summarize key points and aim for a summary slide, which involves managing the meeting flow.",
            "summarize conversation": "The speaker is also summarizing the aim of the group, which is to have one slide with key questions discussed."
        }
    },
    {
        "utterance": "Aida Ebrahimi: you think we can ",
        "annotations": {
            "ask question": "The speaker is seeking input or opinions from others, which is a direct request for information or clarification."
        }
    },
    {
        "utterance": "Amina Schartup: Well I if I can jump in, I mean, to me as someone who like, you know, this discussion is really, really interesting. ",
        "annotations": {
            "supportive response": "The speaker is expressing a positive sentiment towards the discussion, showing engagement and interest."
        }
    },
    {
        "utterance": "Chris Whidbey: What are your questions? ",
        "annotations": {
            "ask question": "Chris Whidbey is requesting information (questions) from the group.",
            "encourage participation": "Chris Whidbey is inviting others to contribute their questions, thereby encouraging participation."
        }
    },
    {
        "utterance": "Amina Schartup: I think I think for me the big themes that came out of it were that I mean what isn't? I thought that was a really interesting question. You know, like what isn't? And that this um you know, this whole idea of the systems is is very, very complex. ",
        "annotations": {
            "summarize conversation": "Amina is summarizing her understanding of the discussion, highlighting the complexity of the systems.",
            "identify gap": "Implicitly, Amina acknowledges the complexity and possibly the vastness of the topic, which can be related to identifying gaps in understanding."
        }
    },
    {
        "utterance": "Barbara Bendlin: Sorry, I was on mute. ",
        "annotations": {
            "process management": "The speaker is addressing a procedural issue related to communication flow in the meeting."
        }
    },
    {
        "utterance": "Barbara Bendlin: I was wondering if anyone um could be willing to um work with Chris maybe to um just bring up the PowerPoint. We can start putting our um thoughts into the um PowerPoint. So kind of like a co-reporter role. ",
        "annotations": {
            "ask question": "Barbara is requesting willingness from others to work with Chris.",
            "encourage participation": "Barbara is inviting someone to contribute by working with Chris.",
            "process management": "Barbara is managing the meeting flow by suggesting a co-reporter role."
        }
    },
    {
        "utterance": "Chris Whidbey: Are you okay transcribing our ",
        "annotations": {
            "process management": "Chris Whidbey is inquiring about the status of transcribing the conversation, which is part of managing the meeting's output.",
            "ask question": "Chris Whidbey is directly asking for confirmation or status, which is a clear example of requesting information."
        }
    },
    {
        "utterance": "Barbara Bendlin: Yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: I'm happy to. ",
        "annotations": {
            "supportive response": "Chris Whidbey is expressing agreement and willingness to help with transcribing or summarizing discussions."
        }
    },
    {
        "utterance": "Barbara Bendlin: So that's good. If you're if you're okay typing in into the into the PowerPoint then we can we can let you in as a co-reporter. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow and organizing group activities by discussing the role of a co-reporter and the task of typing into a PowerPoint presentation."
        }
    },
    {
        "utterance": "Chris Whidbey: I think about Wiki gut and microbiome um pages is interesting right and then ties into the vasculature. ",
        "annotations": {
            "develop idea": "Chris Whidbey is expanding on the topic of gut and microbiome pages and their relation to the vasculature, potentially connecting different areas of research.",
            "supportive response": "The statement seems to contribute positively to the discussion, showing interest and attempting to integrate different concepts."
        }
    },
    {
        "utterance": "Chris Whidbey: summarize ",
        "annotations": {
            "summarize conversation": "The speaker is asking for a summary of what has been previously discussed in the meeting."
        }
    },
    {
        "utterance": "Aida Ebrahimi: species identification. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unknown speaker: Do you want to repeat it all again? I can like type fast. ",
        "annotations": {
            "process management": "The speaker is offering to facilitate the process of summarizing or reporting information, which involves managing the meeting flow.",
            "supportive response": "The speaker is expressing a positive and helpful attitude by offering to repeat or summarize information."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Yeah, yeah. It's just a speech that I've had prepared all morning actually. There are a lot of data that already exist out there. Um, so, um, AI needs the data and I think there are a lot of data that are out there. So some data mining, it's not my expertise but I'm sure we have some people that work on these. And that they can mine the data, existing data. Um, there are a lot of reports that they I was actually looking at some review papers like studying germ free um mice and then uh uh some specific SPF mice. So uh those data are out there. So maybe that's one way to mind the mind those data. That the biomarker or species that are involved in these I don't know mechanisms. So the gut metabolome way or anything is to induce. ",
        "annotations": {
            "propose new idea": "The speaker suggests data mining as a new approach to utilize existing data for research.",
            "develop idea": "The speaker elaborates on the concept of data mining and its potential application.",
            "acknowledge contribution": "The speaker recognizes the potential role of others in mining data.",
            "offer feedback": "The speaker provides a suggestion for moving forward with data mining."
        }
    },
    {
        "utterance": "Unknown speaker: So uh you know, I think we got ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: Chris, do you think the one the what you, you know, we if we want to copy what Chris wrote down and divide it between among these three. So uh how they are relevant to these. ",
        "annotations": {
            "ask question": "The speaker is asking Chris for clarification or opinion on organizing information.",
            "acknowledge contribution": "The speaker acknowledges Chris's previous input by referencing what he wrote down.",
            "encourage participation": "The speaker invites Chris to contribute further by asking for his thoughts."
        }
    },
    {
        "utterance": "Unknown speaker: I'm glad I'm not supposed to paper so discussion in three minutes. ",
        "annotations": {
            "express humor": "The speaker makes a humorous remark about not having to present in three minutes.",
            "process management": "The speaker comments on the timing and process of a presentation."
        }
    },
    {
        "utterance": "Unknown speaker: Uh, not really. Thank you for asking. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Yanjiao Zhou: So, so I do feel in the first part of this discussion when we talk about all the different organisms. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing or referring back to previous conversation content about different organisms."
        }
    },
    {
        "utterance": "Yanjiao Zhou: Um are also very interesting so because all those I guess. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Chris Whidbey: I didn't understand as much about understanding as much about that. So maybe just in the end also adding all the summary of all the key phrases. Just it's already although I think that would be very informative for most of the discussion. I don't know if somebody a little more versed than that wanted to summarize. ",
        "annotations": {
            "develop idea": "Chris is expanding on the idea of summarizing discussions to enhance understanding.",
            "ask question": "Chris asks if someone more knowledgeable wants to summarize.",
            "process management": "Chris suggests summarizing key points as a way to manage the discussion process."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I don't know how to summarize it too. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: Chris, would you just a couple of keywords? Are we going to um divide them into three pieces and barely are relevant, right? I don't know what to right. Am I right or no? I I understood it. ",
        "annotations": {
            "ask question": "The speaker is explicitly asking Chris for information or clarification on how to proceed with keywords."
        }
    },
    {
        "utterance": "Chris Whidbey: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: I think that was detection technology. inflammation and immune responses uh affecting. ",
        "annotations": {
            "summarize conversation": "The speaker is attempting to summarize or reflect on previous discussions about detection technology and its relation to inflammation and immune responses."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Really if we identify, so maybe it's a separate thing by itself. If we identify what are those uh biomarkers or species, then we can think about building diagnostics or sensors in for real time analysis or in situ analysis for them. I think that's actually what I heard was that there was really a mixture of in vitro um in vivo models. Um Ashley's looking at intestinal tissue um and then working your way up also, you know, you have controlled germ free animals, then you can also look at humans with and without disease, right? So healthy or with disease. I think they're all important, no? I mean absolutely. And I heard everyone sort of dismissing. So this particular thing I'm highlighting about the sort of dynamics of within the microbiome and the interactions between them. And I wonder just from a straight medicine perspective. And what I heard was that there was really a mixture of in vitro in vivo models. Ashley's looking at intestinal tissue and then working your way up also, you know, you have controlled germ free animals, then you can also look at humans with and without disease, right? So healthy or with disease. I think they're all important, no? I mean absolutely. And I heard everyone sort of dismissing. So this particular thing I'm highlighting about the sort of dynamics of within the microbiome and the interactions between them. And I wonder just from a straight medicine perspective. They can be tools that can be used to monitor different that we haven't complete understanding of and that textbook definition. ",
        "annotations": {
            "propose new idea": "Aida Ebrahimi suggests using a mixture of in vitro and in vivo models for studying the microbiome.",
            "develop idea": "She elaborates on the need to understand the dynamics within the microbiome and interactions between species.",
            "ask question": "Aida Ebrahimi seeks clarification on the importance of understanding the microbiome from a medicine perspective."
        }
    },
    {
        "utterance": "Aida Ebrahimi: One third changes for example, by change I mean if we want to go with the route that we are co-culturing in vitro two different species for example. And we want to study the effect of if we are changing I don't know hormone concentration um in that model. ",
        "annotations": {
            "develop idea": "The speaker is providing a concrete example of an experimental approach to study changes, building on previous discussions.",
            "ask question": "The speaker is seeking to understand how to study the effects of changing hormone concentrations in an experimental model."
        }
    },
    {
        "utterance": "Aida Ebrahimi: It could be in vitro or in vivo like mouse model. So whatever that design is, then we have to have some path to be able to at least that is um one of what one of the things that we discussed is in real time monitor level of those small molecules or those biomarkers in real time without the need to kill them or slice the tissue things like that which is really totally different. Of course those approaches are needed as a standard to compare with. But if we want to see in real time what is going on then those sensors can be integrated or embedded in that in vitro or in vivo model. Of course it needs to make sure for being more complex but there are in my opinion that's what I think you have to have access to all those genomics metabolomics all the omics. ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas about monitoring biomarkers in real-time and discusses potential models.",
            "identify gap": "The speaker highlights the limitation of current biological sampling methods.",
            "offer feedback": "The speaker provides her opinion on the necessity of accessing various omics approaches."
        }
    },
    {
        "utterance": "Aida Ebrahimi: What was that sorry? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification about something previously said."
        }
    },
    {
        "utterance": "Erin Longbrake: Sorry need to. ",
        "annotations": {
            "process management": "Erin Longbrake is indicating a need to end her participation in the discussion, which relates to managing the meeting flow."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Sorry. ",
        "annotations": {
            "None": "The utterance is a brief expression of apology and does not fit into any other specified code category."
        }
    },
    {
        "utterance": "Erin Longbrake: So the overall problem of how do we model specific metabolites kind of one at a time or. What's the limits of the platform? How how multiplex does it get? Yeah, that's a really good point instead of just what the the sort of static microbiome levels are and what are the dynamics of the interactions between them. ",
        "annotations": {
            "ask question": "Erin is requesting information about the methodology for modeling metabolites and the platform's capabilities.",
            "identify gap": "Erin points out the insufficiency of focusing solely on static microbiome levels.",
            "critical response": "Erin's inquiry implies criticism of current approaches for not considering dynamics of interactions."
        }
    },
    {
        "utterance": "Aida Ebrahimi: They do, right? ",
        "annotations": {
            "ask question": "The speaker is seeking confirmation or agreement from others.",
            "supportive response": "The utterance is also supportive as it seeks alignment with others' views."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Norepinephrine serotonin glutamate. There are studies that they showed they definitely relationship. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by referencing specific studies and neurotransmitters, contributing to the discussion.",
            "supportive response": "The utterance supports the ongoing discussion by adding relevant information and referencing existing research."
        }
    },
    {
        "utterance": "Unknown speaker: You know, let me add there's a spatial component too. ",
        "annotations": {
            "develop idea": "The speaker is adding a new point (spatial component) to the discussion, which expands on the current ideas being considered."
        }
    },
    {
        "utterance": "Aida Ebrahimi: What else is there? ",
        "annotations": {
            "ask question": "The speaker is requesting additional information or perspectives beyond what has already been discussed."
        }
    },
    {
        "utterance": "Aida Ebrahimi: There are studies that they showed they definitely relationship. I think you mentioned also some actually. I think you're mentioning about the small intestines. Yeah, yeah, glutamate is that norepinephrine serotonin dopamine uh what else do we have? Some like neurochemicals or you know hormones. Well, I can I can see the the discussion is kind of winding down and that's that's good. I I really enjoyed this guys. Um all the different inputs. Um ",
        "annotations": {
            "supportive response": "The speaker expresses a positive sentiment towards the discussion and participants, indicating a supportive attitude.",
            "summarize conversation": "The speaker attempts to wind down the discussion, indicating an effort to summarize or conclude the conversation."
        }
    },
    {
        "utterance": "Barbara Bendlin: And what I heard was that there was really a a mixture of in vitro um in vivo models. Um Ashley's looking at intestinal tissue um and then working your way up also, you know, you have controlled germ free animals, then you can also look at humans with and without disease, right? So healthy or with disease. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing previous discussions about the types of research models being considered."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I think they're all important, no? ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with previous statements, showing a positive evaluation of the contributions made."
        }
    },
    {
        "utterance": "Barbara Bendlin: Absolutely. and I heard everyone sort of dismissing. ",
        "annotations": {
            "Supportive Response": "The speaker expresses agreement with a previous statement.",
            "None": "No other code seems to directly apply beyond supportive response and possibly summarize conversation, but the latter is less directly observed."
        }
    },
    {
        "utterance": "Unknown speaker: Yeah, so ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: Yeah. ",
        "annotations": {
            "None": "The utterance is a brief acknowledgment without adding substantial content."
        }
    },
    {
        "utterance": "Aida Ebrahimi: In terms of humans. I mean I was reading papers it seems like the patients like really like clinical experiments. There are already a lot of like mass spec data that people that they are part of these studies, the data is available. So um ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by mentioning available mass spec data from previous studies."
        }
    },
    {
        "utterance": "Unknown speaker: So all of these questions relate to right. ",
        "annotations": {
            "summarize conversation": "The speaker is attempting to relate or summarize various questions that have been discussed, indicating a connection between them."
        }
    },
    {
        "utterance": "Aida Ebrahimi: Yeah, yeah. glutamate is that norepinephrine serotonin dopamine uh what else do we have? ",
        "annotations": {
            "ask question": "The speaker is seeking additional information or examples of metabolites/neurotransmitters.",
            "develop idea": "The speaker is building upon existing knowledge by discussing specific neurotransmitters/metabolites."
        }
    },
    {
        "utterance": "Unknown speaker: You know, let me add there's a spatial component too. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aida Ebrahimi: There are studies that they showed they definitely relationship. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unknown speaker: As a matter of fact, all the studies I've done finds the information after stroke with hypertension or small vessel disease, it all seems to be in the small intestines yet. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Erin Longbrake: So if you want to if you want to add a few comments and if others want to help Chris with the second two. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute their thoughts or help with a task.",
            "process management": "The utterance helps manage the group's activity by encouraging participation in a specific task."
        }
    },
    {
        "utterance": "Aida Ebrahimi: you know, correlation. It's not causal, not so much as what as I know. I think there is you don't have causal information like what is exactly going on. That's one of the big big issues, right? ",
        "annotations": {
            "identify gap": "The speaker is explicitly recognizing a gap in current research capabilities, specifically the inability to determine causal relationships."
        }
    },
    {
        "utterance": "Erin Longbrake: What kind of tools do we mean and how can we make sure you have the right expertise to build them. ",
        "annotations": {
            "process management": "Erin Longbrake is managing the discussion flow by seeking clarification on the specifics of tools and expertise required, directing the conversation towards more detailed understanding."
        }
    },
    {
        "utterance": "Erin Longbrake: My internet has been wonky. I'll try to see if I can get it more reliable over the next. ",
        "annotations": {
            "process management": "The speaker is addressing a logistical issue (their internet connection) that might affect their participation in the meeting."
        }
    },
    {
        "utterance": "Aida Ebrahimi: We also talked about um you talked about niche like um an easy digestible review. ",
        "annotations": {
            "summarize conversation": "The speaker is reflecting on previous discussions, indicating an attempt to summarize or guide the conversation forward based on what has been previously discussed."
        }
    },
    {
        "utterance": "Flavio Frohlich: Well, I think at multiple levels, but uh the the original thought I I proposed to the group I believe was that if we have um uh these assets, we need to be strategist by now to develop models of the interaction and kind of the the maybe grouping or clustering of um let's say envision metabolites or whatever whatever level of analysis we're choosing. ",
        "annotations": {
            "develop idea": "Flavio Frohlich is expanding on a previous thought he proposed to the group, discussing the need to develop models of interaction.",
            "summarize conversation": "Flavio Frohlich is summarizing his previous proposal to the group about developing models of interaction and possibly grouping or clustering metabolites."
        }
    },
    {
        "utterance": "Andrew Feig: I tell you what, I just dropped in the resource like I think uh yeah, I did. It's group 1.2 system level. You know, a couple days ago or maybe it was even yesterday. I just I just put a few key terms in and pulled up some papers. Some I I haven't read any of them. I shouldn't say that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mei Shen: So I see how also I should mention about the back here. So do you already include that or? ",
        "annotations": {
            "ask question": "Mei Shen is requesting information or confirmation about whether something has been included."
        }
    },
    {
        "utterance": "Shikha Nangia: Yeah, I don't see the way I was describing it, but that was like sort of a thought experiment to start with uh mice with no uh microbiota but progressively introduce complexity. ",
        "annotations": {
            "propose new idea": "The speaker introduces a thought experiment involving mice with no microbiota and progressively introducing complexity as a new approach to studying the microbiome."
        }
    },
    {
        "utterance": "Barbara Bendlin: Could you add 4.1? Um the idea being start with germ free mice at microbiota and do metabolomics. ",
        "annotations": {
            "Process management": "Barbara Bendlin is managing the meeting flow by instructing someone to add a specific point (4.1) related to an experimental approach."
        }
    },
    {
        "utterance": "Andrew Feig: Well, you know, another aspect of that that I'm worried about. And that is there's some tools out there that I don't know about. And you know, they're new tools and that's the reason and uh. ",
        "annotations": {
            "identify gap": "The speaker is expressing concern about a gap in his knowledge regarding new tools that exist but are unknown to him."
        }
    },
    {
        "utterance": "Andrew Feig: I I think it's just fascinating that I stumble on this. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Barbara Bendlin: And then bringing the data science and machine learning into the process. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of integrating multiple disciplines into the research process by mentioning bringing data science and machine learning into the process."
        }
    },
    {
        "utterance": "Andrew Feig: Yeah, that you know in principle, right? ",
        "annotations": {
            "supportive response": "The utterance expresses agreement or validation without adding new content."
        }
    },
    {
        "utterance": "Barbara Bendlin: It sounds from that like you could imagine like a workshop where people just like present all the tools that they that are available and other scientists could go and and sort of find the things that are most relevant. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea about organizing a workshop for scientists to present and discover tools relevant to their research.",
            "develop idea": "The suggestion of a workshop builds upon the context of previous discussions about advancing microbiome research and tool development."
        }
    },
    {
        "utterance": "Shikha Nangia: So I'm trying to see within the group if there is some some correlation around the topic that we can think of. I totally agree that a bigger group is also um explaining from the science end like what specific thing is needed. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of collaboration and finding correlations within the group.",
            "supportive response": "The speaker agrees with the notion of a bigger group providing more scientific explanations.",
            "encourage participation": "The speaker encourages finding correlations within the group."
        }
    },
    {
        "utterance": "Aida Ebrahimi: I think the goal would be all the different groups they report out then it it is a there will be okay, some thinking by by people then just reaching out to each other. Maybe this group, I don't know, like just among uh group 11. But I think that's not what what Andrew said. ",
        "annotations": {
            "acknowledge contribution": "The speaker references Andrew's previous statement, acknowledging his contribution to the discussion.",
            "process management": "The speaker discusses the process of groups reporting out and members reaching out to each other, which pertains to managing group activities.",
            "clarify goal": "The speaker is reflecting on and trying to understand the goal of the reporting process among different groups."
        }
    },
    {
        "utterance": "Barbara Bendlin: You can start thinking about it. So that not necessarily this group will be like a final research group, but you know, think about who you met here today and you can reach out to whose research, you know, sounds like it might mesh with some of your ideas and then you'll be able to reach out to one another to form these teams. ",
        "annotations": {
            "encourage participation": "The speaker encourages team members to think about who they met and whose research might mesh with their ideas to form teams."
        }
    },
    {
        "utterance": "Shikha Nangia: Yeah, I think trying to see within the group if there is some some correlation around the topic that we can think of. I totally agree that a bigger group is also. ",
        "annotations": {
            "Supportive response": "The speaker is expressing agreement and a positive evaluation of the idea.",
            "Develop idea": "The speaker is building upon the previous idea by suggesting exploring correlations within the group."
        }
    },
    {
        "utterance": "Andrew Feig: part of the assessment of the Syllog program at large. So um uh they are actually recording the sessions. This is something I'll just say while we're waiting for everyone to be back in the room. One of the things we do is is a study of how new collaborations form and what happens at the meetings that help to lead that so that we can adjust the nature of the meeting. ",
        "annotations": {
            "process management": "The speaker is discussing the study of how new collaborations form and how meetings help lead to that, in order to adjust the nature of the meeting."
        }
    },
    {
        "utterance": "Andrew Feig: Um and so we have data now 10 years running on. ",
        "annotations": {
            "summarize conversation": "Andrew Feig is providing an update on the data they have collected over 10 years, which could be related to summarizing previous conversations or setting the stage for further discussion."
        }
    }
]